OR WAIT null SECS
July 19, 2024
Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.
October 12, 2023
The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.
June 20, 2023
The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally.
February 23, 2023
GAO calls for more oversight of institutional review boards in clinical trials.
January 13, 2023
It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.
December 01, 2022
Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.
November 30, 2022
The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.
November 17, 2022
CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.
August 10, 2022
The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.
July 02, 2022
Finding specific solutions to overcome uncertainty has led to the evolution of a new clinical trial research environment.